Several well-established clinician ratings are used in Parkinson’s clinical trials, such as the UPDRS, which have led to successful drug approvals.
However, with increasing research and development into new wearable sensors, artificial intelligence, and remote assessment, there is increasing interest and activity in the development and validation of novel endpoints.
In episode eight of our "Clinical Viewpoints" video series, Lew Fredane, Clinical Vice President and Therapeutic Area Leader for neurology at Signant, discusses novel endpoints in PD trials.
